A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase of Trial: Phase I/II
Latest Information Update: 24 May 2018
At a glance
- Drugs CWP 291 (Primary) ; Cytarabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
- 24 May 2018 Phase has been changed from I to I/II. Planned number of patients has also changed from 40 to 45.
- 11 May 2018 Planned number of patients changed from 40 to 45.
- 11 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Oct 2020.